Table 5.
Late radiotherapy toxicity (online)
| CXRT (n = 80) grade |
CXRT+R115777 (n = 78) grade |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||||
| 1 | 2 | 3 | 4 | 5 | 1 | 2 | 3 | 4 | 5 | |
| Small/large intestine | 2 | 3 | 0 | 0 | 0 | 4 | 0 | 1 | 0 | 0 |
| Skin | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Subcutaneous tissue | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other | 2 | 0 | 4 | 0 | 0 | 0 | 1 | 2 | 0 | 0 |
| Worst late toxicity | 5 (6.3%) | 2 (2.5%) | 4 (5%) | 0 (0%) | 0 (0%) | 3 (3.8%) | 1 (1.3%) | 2 (2.6%) | 0 (0%) | 0 (0%) |
Note: Toxicities were graded with RTOG/EORTC late toxicity criteria.
Abbreviations: CXRT, concurrent radiation with gemcitabine and paclitaxel; R115777, farnesyl transferase inhibitor; EORTC, European Organization for Research and Treatment of Cancer; RTOG, Radiation Therapy Oncology Group.